What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
The scientist’s investigation covers issues in Melanoma, Internal medicine, Surgery, Oncology and Cutaneous melanoma.
Claus Garbe is studying Vemurafenib, which is a component of Melanoma.
Randomized controlled trial is closely connected to Gastroenterology in his research, which is encompassed under the umbrella topic of Internal medicine.
His Surgery research is multidisciplinary, incorporating elements of Placebo, Clinical trial, Cobimetinib and Hazard ratio.
His research in Oncology intersects with topics in Multivariate analysis, Dabrafenib, Proportional hazards model, Binimetinib and Survival analysis.
Claus Garbe interconnects Epidemiology, Dermatology, Guideline, Physical examination and Adjuvant therapy in the investigation of issues within Cutaneous melanoma.
His most cited work include:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma (3248 citations)
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma (1574 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Melanoma, Internal medicine, Oncology, Surgery and Cancer research.
His Melanoma study integrates concerns from other disciplines, such as Dermatology, Metastasis and Pathology.
His work in Internal medicine covers topics such as Gastroenterology which are related to areas like Adverse effect.
His Oncology research incorporates elements of Metastatic melanoma, Clinical trial, Chemotherapy, Phases of clinical research and Immunology.
The various areas that Claus Garbe examines in his Cancer research study include PI3K/AKT/mTOR pathway and MAPK/ERK pathway.
He combines subjects such as MEK inhibitor and Trametinib with his study of Vemurafenib.
He most often published in these fields:
- Melanoma (53.45%)
- Internal medicine (37.77%)
- Oncology (29.11%)
What were the highlights of his more recent work (between 2015-2021)?
- Melanoma (53.45%)
- Internal medicine (37.77%)
- Oncology (29.11%)
In recent papers he was focusing on the following fields of study:
Claus Garbe mainly focuses on Melanoma, Internal medicine, Oncology, Cancer research and Immunotherapy.
Claus Garbe has researched Melanoma in several fields, including Targeted therapy and Immunology.
His study connects Surgery and Internal medicine.
His study looks at the relationship between Oncology and fields such as Clinical trial, as well as how they intersect with chemical problems.
His Cancer research research includes elements of Neuroblastoma RAS viral oncogene homolog, PI3K/AKT/mTOR pathway and MAPK/ERK pathway.
His research on Ipilimumab also deals with topics like
- Nivolumab and related Pembrolizumab,
- Randomized controlled trial and related Gastroenterology.
Between 2015 and 2021, his most popular works were:
- Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. (459 citations)
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. (322 citations)
- Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial (320 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
His primary areas of study are Melanoma, Internal medicine, Oncology, Surgery and Ipilimumab.
He is interested in Vemurafenib, which is a branch of Melanoma.
His studies deal with areas such as Clinical trial, Chemotherapy, Dabrafenib and Binimetinib, Trametinib as well as Oncology.
His Surgery study incorporates themes from Radiology and Incidence.
His studies in Ipilimumab integrate themes in fields like Biomarker, Cytotoxic T cell, Gastroenterology and Surrogate endpoint.
His Cancer research also works with subjects such as
- Stage that intertwine with fields like Cohort and Cutaneous melanoma,
- Guideline and related Radiation therapy, Lymph node and Dermatology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
